Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Sponsors Took Delivery Device Shortcuts For Erelzi, Amjevita

Executive Summary

Sandoz’s and Amgen’s biosimilars employ autoinjectors that are currently used with the sponsors’ novel biologic products, allowing them to avoid additional human factors study testing of the delivery devices.

Advertisement

Related Content

Drug Review Profiles: Behind The Scenes At US FDA
Mapping US FDA's Biosimilar Pathway With Pink Sheet Drug Review Profiles
Erelzi Clinical Development Timeline
Sandoz Tested Erelzi’s Suffix On Multiple Fronts
Interchangeability: FDA Sets ‘Stringent’ Standard On Design Differences
Biosimilar Labeling Variation From Reference Product OK, FDA Says
Zarxio Syringe’s Limitations May Delay Decision On Neupogen Interchangeability

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel